Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence

Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with <i>BRAF</i>-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore...

Full description

Bibliographic Details
Main Authors: Paweł Rogala, Anna M. Czarnecka, Bożena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Ziętek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Natasza Kempa-Kamińska, Jacek Calik, Agata Sałek-Zań, Tomasz Zemełka, Wiesław Bal, Agnieszka Kamycka, Tomasz Świtaj, Grażyna Kamińska-Winciorek, Rafał Suwiński, Jacek Mackiewicz, Piotr Rutkowski
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
melanoma
<i>BRAF</i>
dabrafenib
vemurafenib
encorafenib
Online Access:https://www.mdpi.com/2077-0383/11/8/2239

Similar Items

Similar Items